Purpose: Malignant transformation in the prostate produces significant alterations in glandular architecture (Gleason grade) and nuclear structure that provide valuable prognostic information. Normal-appearing nuclei (NN) adjacent to cancer may also have altered functions in response to malignancy. We studied NN adjacent to peripheral zone (PZ) prostate cancer (PCa), as well as the PZ cancer nuclei (CaN) using quantitative image cytometry. The nuclear structure information was combined with routine pathological findings to predict metastatic PCa progression and/or death.
INTRODUCTION
Over the past two decades there have been tremendous changes in the diagnosis and management of prostate cancer. The widespread use of serum prostate-specific antigen (PSA), along with transrectal ultrasound-guided prostate biopsy, and improved acceptance of early detection has produced a marked increase in prostate cancer incidence in the United States during the 1990s (1, 2) . Improvements in surgical technique have substantially reduced perioperative morbidity (3) . Approximately 75% of men newly diagnosed with prostate cancer today present clinically with nonpalpable disease (stage T1c) and are regarded as potentially curable with definitive intervention (surgery or radiation). However, ϳ25% of this population will experience biochemical recurrence over a 10 -15-year period after treatment (4 -6) . The majority of men that have a PSA recurrence will experience distant metastases and/or die from prostate cancer at intervals ranging from 1 to 13 years after PSA recurrence (6) . Improved methods to predict these intervals are greatly needed.
Image cytometry has provided one tool to detect cancer and assess recurrence and progression at the tissue architecture and cellular level (7) (8) (9) (10) (11) . Imaging systems, both flow and static, are able to perform DNA ploidy and quantify several nuclear morphometric descriptors (NMDs), which are useful to gain supplemental diagnostic and prognostic information from clinical specimens (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . Several investigators have applied nuclear morphometry to assess the precursor lesions (e.g., high-grade prostatic intraepithelial neoplasia), as well as cancer-adjacent normal nuclei, to occult but histologically not evident prostate cancer (14, 20 -23) .
Our group used the Cell Analysis System (CAS-200; Ref. 12 ) to produce quantitative nuclear grade (QNG) solutions from a single 5-m histological section or a cytology preparation for prediction of clinical, diagnostic, and prognostic outcomes in both prostate and bladder cancer (15) (16) (17) (18) (19) . The current study used prostate tissue microarrays (TMAs) to derive QNG solutions from the cancer area nuclei (CaN) and from normal nuclei (NN) collected adjacent to the peripheral zone prostate cancer area. These QNG solutions were used to predict, at the time of definitive surgery, the time to distant progression for 182 men with long-term follow-up who experienced PSA recurrence after radical prostatectomy.
MATERIALS AND METHODS
Patient Population and Creation of TMAs. The mean age of the 182 men was 60 years (range ϭ 42-75 years), and none had received neoadjuvant radiation or hormonal therapy. The mean follow-up time for the biochemical recurrence (PSA level Ͼ 0.2 ng/ml) and the biochemical recurrence with distant metastasis and/or death groups were 12.5 years (median ϭ 13 years, range ϭ 4 -19 years) and 10.6 years (median ϭ 6 years, range ϭ 2-20 years), respectively. Of these 182 men, 88 (48%) experienced biochemical recurrence without evidence of distant metastasis (i.e., nonprogression), whereas 94 (52%) either progressed to distant metastases or died from prostate cancer (i.e., progression) after their initial PSA recurrence. All clinical, demographic, pathological, and follow-up data, as well as the pathological material, were collected under an Internal Review Board approved protocol that passes Health Insurance Portability and Accountability Act compliance. Informed consent was obtained prior to surgery and where appropriate for long-term follow-up.
Slides from all 182 cases were reviewed and mapped by a single pathologist and the normal-appearing and index tumor areas, usually defined as the largest and/or highest Gleason score were identified and marked on the slide for each case. Using these template slides marked for normal-appearing and diagnostic cancer areas, the tissue blocks were coordinately marked using the template slides, and 2-mm cores were punched from the normal-appearing and tumor areas and then transferred to recipient blocks. The TMAs were prepared for all 182 cases (both normal-appearing and cancer areas) using a Beecher MT1 manual arrayer (Beecher Instruments, Silver Spring, MD) in the Johns Hopkins University Specialized Programs of Research Excellence grant pathology core facility. Each TMA was con- structed using four replicate 2-mm core tissue samples from the normal-appearing and cancer areas of each patient who had undergone radical prostatectomy for PCa. Each block had an orientation marker and contained internal controls placed in a pre-established pattern throughout each one of the blocks to assess quality of the Feulgen stain throughout the histological sections. A total of five blocks was created for the 182 cases and controls. Slides prepared from each of the TMA blocks were stained with H&E, and the normal-appearing and cancer areas for each patient's core set were reviewed by a pathologist to ensure their diagnostic accuracy.
Preoperative Evaluation and Pathological Characteristics. The men were staged according to the 1992 American Joint Committee on Cancer staging guidelines (24) , including digital rectal examination by a single surgeon and routine serum PSA studies (Hybritech and Tandem-R and EC Beckman Coulter, San Diego, CA and TOSOH, Tosoh Medics, San Francisco, CA). Preoperative pathological diagnosis of PCa was based on examination of prostatic tissue obtained by transrectal ultrasound or digital guided prostate biopsy or from transurethral resection of the prostate. On the basis of clinical and pathological evaluation, tumors were determined to be organconfined, to exhibit extraprostatic extension without positive surgical margins, extraprostatic extension with positive surgical margins, or seminal vesicle involvement without nodal disease, or to have spread to pelvic lymph nodes (25, 26) .
Patient Follow-Up and Definitions of Progression. Postoperative follow-up was obtained through routine serum PSA assays and digital rectal examinations performed every 3 months for the first year, semiannually the second year, and annually thereafter. Isolated biochemical PSA elevation was defined as a serum PSA level Ն 0.2 ng/ml. Radionuclide bone scans were performed at the time of biochemical recurrence and on a yearly basis thereafter unless performed earlier for symptoms suggestive of bone metastasis. A positive bone scan result or other radiographic or histological (lymph node biopsy) evidence was used for the diagnosis of distant metastasis.
QNG Determination. The methods of QNG calculation have been reported previously (16 -18) . Using 5-m sections prepared from the TMA blocks, Feulgen staining was performed per instructions in the staining package insert (TriPath Imaging, Inc., Burlington, NC). Next, a minimum of 100 intact Feulgenstained CaN and NN were captured from each case using all four 2-mm spots/case of the TMAs using an AutoCyte Pathology Workstation (TriPath Imaging, Inc.) and the QUIC-DNA software (16 -18) . The QUIC-DNA software calculated a total of 60 NMDs, including nuclear size, shape, DNA content, and chromatin texture features (at a step size of one pixel), for each nuclei captured from both the CaN and NN cases. Next, the variance of each NMD for the CaN or NN captured from each case was calculated (16 -18) .
Statistical Analysis. All data were analyzed with Stata version 8.0 statistical analysis software (Stata Corporation, College Station, TX). A nonparametric k-sample test for the equality of medians was used to evaluate differences in the nonnormally distributed ages and preoperative serum PSA levels, whereas Wilcoxon's rank-sum test was used to test for distribution differences in the clinical stage and the biopsy and pathological Gleason scores. Pearson's 2 test was used to test for independence of surgical margin status, capsular penetration status, organ confinement status, seminal vesicle status, and lymph node status. Multivariate logistic regression (MLR) analyses were used to construct models and to calculate areas under the receiver operator characteristic curves, sensitivities, specificities, and accuracies for the differentiation of the two groups of men (i.e., biochemical recurrence only versus biochemical recurrence with distant metastasis and/or death). Cox proportional hazard ratios and Kaplan-Meier survival plots were created to demonstrate the ability of QNG and routine pathological variables, both separately and in combination, to predict patient outcome.
RESULTS
The patient sample demographics and the analysis thereof are shown in Table 1 . The analysis of differences between the two status groups demonstrated that clinical stage, postoperative pathological Gleason score, seminal vesicle status, lymph node status, and organ confinement status were all univariately statistically significantly different (P Ͻ 0.05), but notably, biopsy Gleason score was not significant. Table 2 illustrates the ability of QNG-NN and QNG-CaN solutions and routine pathology (that included pathological Gleason score, lymph node status, seminal vesicle status, surgical margin status, capsular penetra- tion status, and the organ confinement status) to predict the binary outcome using MLR analysis in the entire patient cohort. The results show that QNG-NN and QNG-CaN can each predict the outcome significantly better than routine pathology (i.e., based on improved specificity and accuracy) even when pathology was evaluated at two different stringencies. Also, there was no statistically significant difference between the areas under the receiver operator characteristic for QNG-NN and QNGCaN. The addition of the pathology variables to the QNG biomarkers significantly improved the MLR model results ( 2 , P Ͻ 0.02).
Next, we compared the optimal QNG-CaN and QNG-NN solutions of each patient and only a total of 40 of 60 NMDs were used to calculate a solution for each outcome group. Table 3 demonstrates the NMD profile for each model (i.e., QNG-CaN and QNG-NN) using a MLR variable selection cutoff (i.e., stringency) of P z Յ 0.15. The comparison reveals that 58% of the NMDs were different for the QNG-CaN versus the QNG-NN solutions; however, both QNG solutions were able to predict the binary outcome of biochemical recurrence and distant metastasis and/or death. Note that NMDs representing nuclear size, shape (ϩ3), and chromatin texture factors (ϩ8) were important in the derivation of the QNG-CaN solution.
Cox hazard regression and Kaplan-Meier survival plots were used to compare the ability of the QNG-NN and QNGCaN solutions and the two multivariately significant pathology variables (prostatectomy Gleason score and lymph node status) to predict the time to distant metastasis and/or death. Several groupings of the two pathology variables were generated, and the survival curves for these groups exhibited considerable overlap and hence were additionally combined to generate the three statistically different risk groups for predicting the time to distant metastasis and/or death ( Fig. 1 and Table 4 ). Note that 66 of 102 (ϳ65%) of men with Gleason scores Ͻ 8 and negative lymph nodes (i.e., groups 1 and 2) were correctly predicted and had a median time to distant metastasis and/or death of Ͼ18 years, whereas 58 of 80 (72.5%) men with positive lymph nodes or a Gleason score Ն 8 (i.e., group 3) were correctly predicted and had a median time to distant metastasis and/or death of ϳ7 years.
To characterize the ability of the QNG-NN and QNG-CaN solutions to predict the time to distant metastasis and/or death, we also partitioned each of them into several groupings as above until we produced only three different risk groups for each QNG solution to predict the outcome (Figs. 2, A and B) . For the QNG-NN solution ( Fig. 2A and Table 5 ), 56 of 71 (ϳ79%) of men with a QNG value of Ͻ0.394 (group 1) were correctly predicted and had a median time to distant metastasis and/or death of Ͼ18 years. In group 2, 30 of 93 (32.5%) men with a QNG-NN value between 0.395 and 0.894 were correctly predicted and had a median time to distant metastasis and/or death of ϳ9 years. Although the numbers were small in group 3, 16 of 18 (ϳ89%) men with a QNG-malignancy-associated change value Ͼ 0.894 were correctly predicted and had a median time to distant metastasis and/or death of ϳ8 years. For QNG-CaN group (Fig. 2B and Table 6 ), a QNG value of Ͻ0.394 (Group 1) consisted of 49 of 61 (ϳ80%) men being correctly predicted and had a median time to distant metastasis and/or death of Ͼ18 years. For men in group 2, 39 of 109 (ϳ36%), with a QNG value between 0.395 and 0.894, were correctly identified and had a median time to distant metastasis and/or death of ϳ9 years. Although the numbers were small in group 3, men with a QNG value Ͼ 0.894 (12 of 12; 100%) were correctly identified and had a median time to distant metastasis and/or death of ϳ4 years.
We also applied the same approach as above to create three distinct risk groups for the combination of the QNG-NN solution and the two multivariately significant pathology variables, yielding the results summarized in the Fig. 3 and Table 7 . This figure illustrates the ability of the combination of the QNG-NN solution with the pathological Gleason score and the lymph node status to stratify men with biochemical recurrence into three different risk groups and predict their time to distant metastasis and/or death. The combination scenario (shown in the Fig. 3 ) provided a solution where the median time to distant metastasis and/or death for men in the low-risk group 1 was Ͼ18 years with 60 of 77 (ϳ80%) correctly identified. In the moderate-risk group 2, there were a total of 39 men with a median distant metastasis-free survival time of ϳ14 years. For the men in the high-risk group 3, 59 of 66 (ϳ89%) were correctly identified and had a median survival time of ϳ6 years.
The difference between each of these three survival curves was highly statistically significant (log-rank and Wilcoxon Ps Յ 0.0001), and the Cox hazard's ratio was 3.15, with a very significant 2 value (77.90). Similar results were obtained for the combination of the QNG-CaN with the pathology variables (Fig. 4 and Table 8 ).
Finally, using MLR and areas under the receiver operator characteristic analyses, we evaluated the ability of the QNG-NN and QNG-CaN solutions to predict the metastasis and/or death outcome compared with the pathology variables alone in a subset of our n ϭ 182 patient cohort that lacked lymph node involvement. Table 9 summarizes the results for a subset of 136 of 182 cases that lacked lymph node involvement (77 biochemical recurrences, 59 biochemical recurrences with distant metastasis and/or death). Table 9 clearly illustrates that in this subset of lymph-node-negative men, QNG-NN and QNG-CaN both performed equivalently and both performed significantly better ( 2 , P Ͻ 0.02) when compared with the pathology MLR model (a multivariate model that retained surgical margin status, seminal vesicle status, and the postoperative Gleason score). The combination of the three variable pathology model with the QNG-CaN solution showed a significant improvement in the a Quantitative nuclear grade normal-appearing nuclei.
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Research. 
DISCUSSION
Using a clinically based retrospective approach, Pound et al. (6) demonstrated that the time to biochemical progression (Յ2 years), prostatectomy Gleason score (Ͼ7), and PSA doubling time (Յ10 months) predicted the time to the development of distant metastatic disease. Currently, the concept of immediate adjuvant therapy for those men most likely to harbor aggressive disease and having an increased risk of developing metastatic disease has gained a great deal of interest because it has been shown to provide some benefit (27) . Therefore, it is very important to be able to predict the likelihood of developing bone metastasis at or after surgery based in part on the tissue-derived pathology variables. The analysis of quantitative alterations in nuclear morphometry has been thoroughly assessed using a variety of manual and computer-assisted imaging systems and has been found to be a strong predictor of outcome in prostate cancer (28 -31) .
Bartels and Wied (7) and Bartels (8) applied quantitative histomorphometry and nuclear chromatin texture measurements in oncology to demonstrate presence of cancer in an organ system using information extracted from noncancerous sites. Palcic's group (10) demonstrated that chromatin texture could be measured reproducibly by image analysis to assess malignancy-associated changes (19) . Mairinger et al. (23) used an automated CytoSavant imaging system, and their technique required the dissociation of cell nuclei from two 50-m formalin-fixed, paraffin-embedded sections that had been marked to identify the cancer and adjacent normal-appearing cells. Their imaging protocol used 114 NMDs to analyze nuclei dissociated from the archival specimen blocks of 63 benign prostatic hyperplasia and 173 PCa cases. They were able to differentiate cancer and benign prostatic hyperplasia cases with a sensitivity of 90% and specificity of 97% using four nuclear texture features (mean fractal dimension, SD, density light spot, and fractal area SD).
Our research group has pursued several applications of the NMDs to predict prostate cancer stage, recurrence, and progression (15) (16) (17) . Recently, we replaced the CAS-200 instrument with the newer AutoCyte Pathology Workstation from TriPath Imaging, Inc. (17) (18) (19) . The current study investigated 182 of 304 men with biochemical recurrence previously investigated by Pound et al. (6) . We demonstrated that both the NN and CaN solutions (QNG-NN and QNG-CA) can predict the outcome; however, 58% of the selected NMDs were different (Table 3) . Notably, the QNG-CaN solution used several cancer-related nuclear features, including 3 additional size and shape factors and 8 chromatin texture factors not used in the calculation of the normal-appearing QNG-NN solution. Our results clearly demonstrate that nuclear morphometry measurements of normalappearing nuclei near peripheral zone cancers may represent malignancy-associated changes. The observation that one can derive a QNG solution from this area (QNG-NN) that can predict distant metastases and/or death requires confirmation. Also, Cox hazard ratios for QNG-NN (2.59) and QNG-CaN (3.74) compared quite favorably with combined pathological Gleason score and lymph node status variables (2.99). Clearly, when QNG-NN or QNG-CaN was combined with pathology (Gleason score and lymph node status), the three resulting risk groups were significantly different and showed improvement over the use of each set of variables alone.
Today, new prognostic challenges exist in contemporary patients presenting with prostate cancer. In particular, pathological Gleason scores are predominantly 6 or 7, and positive lymph node status is only detected in ϳ5% of men, reducing the prognostic value of routine pathology alone as a predictor of disease outcome (27, 32) . In an attempt to address this dilemma, we also evaluated the ability of QNG-NN or QNG-CaN solutions, as well as all available routine pathological variables shown in Table 1 in a subset of 136 lymph node-negative patients from our 182-case TMA study. The QNG-NN or QNGCaN solutions performed significantly better ( 2 value was P Ͻ 0.02) than the multivariately significant routine pathology variables alone (Table 9 ). These results demonstrate that the QNG biomarker in this challenging prognostic setting outperformed routine pathology variables alone under conditions, where patients do not possess overt evidence of advanced disease.
The demonstration of alterations in nuclear structure and DNA organization in normal epithelium adjacent to the cancer area may represent another measure of a field effect. The concept is not a new one and has been demonstrated by others using gene expression, as well as imaging techniques (10, 20 -23, 33) .
Although our studies support the clinical value of computer-assisted image analysis to assess nuclear structure alterations, we appreciate that there remain significant limitations associated with our study. We clearly recognize a need for significant expansion of our training set and a requirement for separate validation sets possessing similar patient demographics. Care must be taken to not overfit our MLR models, and we did perform drop-one analysis and cross-validation to assess the contribution of the NMDs retained in our models. However, ultimately a larger patient sample and a well-balanced validation set matched for distant metastasis and death statistics will be required. Other limitations include the use of archival pathological specimens from a noncontemporary cohort of patients, the need for an expert pathologist to select the most appropriate histological area of clinical importance, and finally, the requirement for an image cytometrist trained to capture the appropriate cell nuclei. As one approach to address the issue of reproducing our results, the AutoCyte cytometry hardware and software with training are commercially available from TriPath Imaging, Inc., and they can be configured to the exact specifications of the instrument and software containing all of the required equations we describe in our article. Finally, the ability of QNG to detect those patients at a high risk of developing distant metastases and/or dying from PCa, after radical prostatectomy, may allow better targeting of those men who would benefit from early available adjuvant therapy and possibly for election of participation in chemoprevention trials. 
